Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Pamiparib |
| Trade Name | |
| Synonyms | BGB-290|BGB290 |
| Drug Descriptions |
Pamiparib (BGB-290) inhibits PARP1 and PARP2, potentially resulting in increased sensitivity to DNA damaging agents (AACR; 2015. Abstract nr 1651, PMID: 32652442). |
| DrugClasses | PARP Inhibitor (Pan) 29 |
| CAS Registry Number | 1446261-44-4 |
| NCIT ID | C120553 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Pamiparib | Bevacizumab Pamiparib | 0 | 0 |
| Cabozantinib + Pamiparib | Cabozantinib Pamiparib | 0 | 1 |
| Fluorouracil + Hydroxyurea + Pamiparib + Tislelizumab | Fluorouracil Hydroxyurea Pamiparib Tislelizumab | 0 | 1 |
| Olaparib + Pamiparib + Temozolomide | Olaparib Pamiparib Temozolomide | 0 | 1 |
| Pamiparib | Pamiparib | 2 | 5 |
| Pamiparib + Radiotherapy | Pamiparib Radiotherapy | 1 | 0 |
| Pamiparib + Temozolomide | Pamiparib Temozolomide | 0 | 6 |
| Pamiparib + Tislelizumab | Pamiparib Tislelizumab | 0 | 3 |